Core Viewpoint - The company has announced a delay in the investment projects funded by raised capital, extending the expected completion dates for two key projects to December 31, 2026 [1][2]. Group 1: Project Delay Announcement - The board of directors approved the extension of the "Intelligent Upgrade of High-end Chemical Equipment Production Line" and "Technical Research Center (Huitong Research Institute)" projects [1][2]. - The delay is attributed to fluctuations in the macroeconomic environment and changes in downstream market demand, leading to an optimization of the investment pace for the projects [2][3]. Group 2: Financial Details of Investment Projects - The total amount of raised funds for the projects is 353.72 million yuan, with 252.30 million yuan allocated for the Technical Research Center project [2][3]. - As of November 30, 2025, the cumulative investment in the Technical Research Center project reached 109.07 million yuan, representing 43.23% of the planned investment [2][3]. Group 3: Impact of the Delay - The delay does not involve changes to the project implementation entities, methods, content, purposes, or investment scales, and is not expected to materially affect the implementation of the projects [2][3]. - The decision to extend the project timeline is considered prudent and aligns with the company's long-term development strategy, aiming to enhance the projects' benefits [2][3].

Core Viewpoint - The company has decided to postpone the completion date of the "5GWh Energy Storage System Construction Project" to April 2026, based on a careful assessment of industry developments and project conditions [4][5][7]. Group 1: Fundraising Overview - The company has received approval from the China Securities Regulatory Commission to issue 30,000,000 shares at a price of RMB 19.27 per share, raising a total of RMB 578.1 million, with a net amount of RMB 569.86 million after deducting issuance costs [2]. - The funds are managed in a dedicated account, with oversight agreements in place with the sponsor and the supervising bank [2]. Group 2: Project Details - The company has outlined the investment status of the fundraising projects as of December 29, 2025, detailing the cumulative investment amounts [3]. - The postponement of the project does not alter the investment subject, purpose, or scale [5][7]. Group 3: Reasons for Delay - The delay is attributed to the rapid evolution of core components in energy storage products, necessitating adjustments to the production line to enhance efficiency and longevity [4]. - The company aims to align the new production line with future mainstream battery technologies [4]. Group 4: Impact of Delay - The postponement is a strategic decision that will not affect the project's implementation or the interests of shareholders, particularly minority shareholders [7]. - The delay is expected to improve capital efficiency and resource allocation, aligning with the company's long-term strategic goals [7]. Group 5: Approval Process - The board of directors approved the postponement during a meeting on December 29, 2025, and the matter does not require shareholder approval [8]. Group 6: Sponsor's Opinion - The sponsor has confirmed that the delay is a prudent decision based on industry conditions and will not change the investment total, subject, or purpose [9][10].

Core Viewpoint - Beijing Ligong Navigation Control Technology Co., Ltd. has announced a delay in the completion date of its fundraising project for the "Inertial Navigation Device Expansion Project" due to the current progress of the project and the need to meet existing order demands [1][5][15]. Fundraising Overview - The company raised a total of RMB 1,434.62 million from its initial public offering, with a net amount of RMB 1,286.16 million after deducting underwriting fees [1]. - As of November 30, 2025, the balance in the fundraising account was RMB 113.53 million, with RMB 113 million used for cash management [3]. Project Delay Details - The delay specifically pertains to the "Inertial Navigation Device Expansion Project," with adjustments made to the expected completion date while maintaining the project's investment scope and purpose [5][7]. - The primary reason for the delay is the company's cautious approach to project construction, focusing on fulfilling existing orders before acquiring additional production equipment [8]. Project Progress and Future Plans - From January to November 2025, contracts for equipment purchases amounting to RMB 10.06 million were signed, with RMB 6.25 million pending payment [9]. - As of November 30, 2025, RMB 24.52 million has been invested in the project, representing 30.63% of the planned investment [9]. - The company anticipates that production capacity will reach 70%-80% of the target capacity upon project completion, aligning with current order demands [9]. Measures to Ensure Completion - The company plans to closely monitor customer demand and optimize product offerings to enhance market share [10]. - It will also increase communication with various units to expedite the development of products currently in research or small-scale production [10]. Re-evaluation of Project Viability - The company has conducted a re-evaluation of the project's feasibility, confirming that it remains aligned with strategic goals and is necessary for future growth [11][14]. - The project is expected to enhance the company's technological capabilities and market competitiveness, contributing positively to long-term performance [13][14]. Impact of the Delay - The delay is deemed a prudent decision that does not alter the project's investment content or total amount, ensuring compliance with regulatory requirements [15][16]. - The company aims to accelerate the project's progress to achieve the intended operational status as soon as possible [15].

证券日报网讯 12月30日，洁特生物发布公告称，洁特生物第四届董事会第二十六次会议审议通过《关 于收购广东洁科膜分离技术有限公司70%股权暨关联交易的议案》《关于部分募集资金投资项目延期的 议案》《关于以集中竞价交易方式回购公司股份的议案》。 （文章来源：证券日报） ...

南财智讯12月30日电，东方钽业公告，公司拟将"钽铌火法冶金产品生产线技术改造项目"达到预定可使 用状态日期由2025年12月31日调整为2026年6月30日。该项目计划投资总额为35,737.88万元，拟使用募 集资金投入金额为30,495.71万元，资金来源为向特定对象发行股票所募资金，主要用于生产线技术升 级。延期原因为进口关键设备德国1600KW垂直电子束熔炼炉因出口许可证审批延误导致到货推迟10个 月，且快锻车间63MN快锻液压机组配套的热态锻件自动化三维测量系统尚未完成研发与调试，影响整 体投产进度。此次延期未改变项目实施主体、用途及投资规模，不会对公司正常经营和整体募资安排产 生重大不利影响，符合公司长远发展需要，不存在变相改变募集资金用途或损害股东利益的情形。 ...

Core Viewpoint - The company has announced an extension of the expected operational readiness date for two projects, which are the "Hunan Changsha MIM Products Production Base Construction Project" and the "Pan Hai R&D Center Construction Project," to June 30, 2026 [1] Group 1: Project Details - The total planned investment for the production base project is 646 million yuan, while the R&D center project is set at 102 million yuan [1] - The funding source for these projects is from the proceeds of the initial public offering, designated for construction purposes [1] Group 2: Reasons for Delay - The delay is attributed to additional business demands from some clients that are expected to be released in the first half of the coming year, necessitating capacity adjustments [1] - Outstanding payments for certain construction works and equipment are also a factor in the delay [1] Group 3: Impact Assessment - The extension does not alter the investment purpose, total investment amount, or the implementing entity of the projects [1] - The company asserts that the delay will not have a substantial impact, will not harm shareholder interests, and complies with relevant fundraising management regulations [1] - Overall, the delay is not expected to negatively affect the company's normal operations or overall fundraising arrangements [1]

Core Viewpoint - The company has decided to extend the implementation deadlines for its fundraising investment projects, specifically the "Innovative Drug R&D Project" to December 2028 and the "Shanghai Junshi Biotech Headquarters and R&D Base Project" to June 2026, without changing the investment content or total amount [1][4][17]. Fundraising Basic Situation - The company was approved to issue 70 million A-shares at a price of RMB 53.95 per share, raising a total of RMB 3,776.5 million. After deducting issuance costs of RMB 31.7 million, the net amount raised was RMB 3,744.8 million, with actual funds received amounting to RMB 3,759.35 million [1][2]. Project Delay Details - The delay in the fundraising projects is based on the company's prudent assessment of the actual progress of the projects, with no changes to the project entities, fundraising purposes, or investment scale [4][17]. - The "Innovative Drug R&D Project" deadline is extended to December 2028 to enhance the efficiency and effectiveness of fund usage, considering the dynamic changes in the innovative drug industry and the company's strategic development [6][9]. - The "Shanghai Junshi Biotech Headquarters and R&D Base Project" deadline is extended to June 2026 due to the complexity of the construction and verification processes, ensuring quality and compliance with regulations [7][8]. Feasibility Analysis of Fundraising Projects - The company possesses excellent drug discovery and development capabilities, covering five major therapeutic areas, and has established a complete technical system for drug development and production [10][12]. - The company has a professional and experienced management and R&D team, with a focus on innovative drug development and a strong emphasis on intellectual property management [13][14]. Impact of Project Delay - The project delay is a cautious decision based on operational needs and actual project conditions, ensuring that it does not adversely affect the company's normal operations or shareholder interests [17][18].

Core Viewpoint - The company has announced a delay in the completion date of its "8,000t/a high-performance NdFeB permanent magnet material project" from December 2025 to September 2026 due to macroeconomic conditions and project cultivation phase impacts [1] Group 1: Project Details - The total planned investment for the project is 1.252 billion yuan, with 1.1 billion yuan sourced from funds raised through a non-public stock issuance [1] - The funds will primarily be used for the construction of a high-performance NdFeB permanent magnet material production line [1] Group 2: Reasons for Delay - The delay is attributed to the need to reduce investment risks and to cautiously advance capacity expansion, resulting in a slower-than-expected equipment selection and procurement process [1] - The postponement does not involve changes to the implementation entity, method, use of raised funds, or investment scale [1] Group 3: Impact on Operations - The delay is not expected to adversely affect the company's normal operations or harm shareholder interests, aligning with the company's long-term development plan [1]

南财智讯12月26日电，时代新材公告，公司拟将"新能源汽车减振制品能力提升项目"的达到预定可使用 状态时间由2025年12月延期至2026年12月。该项目计划投资总额为1.41亿元，拟使用募集资金1.40亿 元，资金来源为2023年度向特定对象发行股票所募资金，用途为提升新能源汽车减振制品生产能力。延 期原因为募集资金于2025年6月26日到账，相关增资至子公司的国资审批及董事会审议程序于2025年12 月26日完成，截至目前尚未完成募集资金划转至子公司专户。本次延期仅为项目进度调整，不涉及实施 主体、实施方式、投资总额及内容变更，不存在变相改变募集资金用途的情形。公司表示，此次延期不 会对公司正常生产经营产生不利影响，未投入的募集资金将根据项目实际进展分阶段投入。 ...

Core Viewpoint - The company, Tianyi New Materials, announced a delay in the expected completion of two key projects due to financial and operational challenges [1] Group 1: Project Details - The "Carbon-Carbon Material Product Line Automation and Equipment Upgrade Project" has a planned fundraising investment amount of 269.76 million yuan, sourced from the proceeds of the initial public offering [1] - The "High-Performance Carbon-Ceramic Brake Disc Industrialization Construction Project" has a planned fundraising investment amount of 1.16 billion yuan, sourced from a private placement of shares [1] Group 2: Reasons for Delay - The delay is attributed to certain fundraising accounts being frozen by the court or restricted by banks, impacting the payment for the projects [1] - The actual investment for the "Carbon-Carbon Material Product Line Automation and Equipment Upgrade Project" has exceeded the original plan, with some equipment still pending delivery [1] - The company has entered a pre-restructuring phase, leading to uncertainties regarding future business directions and the implementation of fundraising projects [1] Group 3: Implications - The delay in these projects may result in a further slowdown in investment progress, potentially affecting the company's main business and overall fundraising arrangements [1] - The company will fulfill its approval and information disclosure obligations in accordance with the progress of the restructuring [1]